- Home
- PSNL vs VSTM Comparison
PSNL vs VSTM Comparison
Compare PSNL & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- VSTM
- Stock Information
- Founded
- PSNL 2011
- VSTM 2010
- Country
- PSNL United States
- VSTM United States
- Employees
- PSNL N/A
- VSTM N/A
- Industry
- PSNL Medical Specialities
- VSTM Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- VSTM Health Care
- Exchange
- PSNL Nasdaq
- VSTM Nasdaq
- Market Cap
- PSNL 321.1M
- VSTM 132.0M
- IPO Year
- PSNL 2019
- VSTM 2012
- Fundamental
- Price
- PSNL $5.19
- VSTM $3.88
- Analyst Decision
- PSNL Strong Buy
- VSTM Strong Buy
- Analyst Count
- PSNL 4
- VSTM 8
- Target Price
- PSNL $6.81
- VSTM $14.57
- AVG Volume (30 Days)
- PSNL 439.4K
- VSTM 1.1M
- Earning Date
- PSNL 11-06-2024
- VSTM 11-06-2024
- Dividend Yield
- PSNL N/A
- VSTM N/A
- EPS Growth
- PSNL N/A
- VSTM N/A
- EPS
- PSNL N/A
- VSTM N/A
- Revenue
- PSNL $80,027,000.00
- VSTM $10,000,000.00
- Revenue This Year
- PSNL $10.85
- VSTM N/A
- Revenue Next Year
- PSNL $8.77
- VSTM $125.69
- P/E Ratio
- PSNL N/A
- VSTM N/A
- Revenue Growth
- PSNL 19.20
- VSTM N/A
- 52 Week Low
- PSNL $0.89
- VSTM $2.10
- 52 Week High
- PSNL $7.20
- VSTM $14.22
- Technical
- Relative Strength Index (RSI)
- PSNL 56.29
- VSTM 63.77
- Support Level
- PSNL $4.54
- VSTM $3.11
- Resistance Level
- PSNL $5.35
- VSTM $3.76
- Average True Range (ATR)
- PSNL 0.30
- VSTM 0.33
- MACD
- PSNL 0.05
- VSTM 0.04
- Stochastic Oscillator
- PSNL 84.71
- VSTM 94.26
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.